Ireland· IE-PA-PA1107/002/001
LIQUIVISC 2.5 mg/g eye gel
A künstliche tränenflüssigkeit und sonstige indifferente präparate product containing carbomer, registered in Ireland by Laboratoires Thea. The same ATC class is registered in 11 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Künstliche tränenflüssigkeit und sonstige indifferente präparate is registered in 11 of 19 countries.
Countries holding a registration under ATC S01XA20 (künstliche tränenflüssigkeit und sonstige indifferente präparate), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 7 of them publish a price we can compare per daily dose
Künstliche tränenflüssigkeit und sonstige indifferente präparate · ATC S01XA20
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
HPRA (Ireland)- Active substance
- Carbomer
- Manufacturer
- Laboratoires Thea
- Country
- Ireland (IE)
- ATC code
- S01XA20
- ATC class
- Künstliche Tränenflüssigkeit und sonstige indifferente Präparate
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberPA1107/002/001
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Künstliche tränenflüssigkeit und sonstige indifferente präparate in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SpainSICCAFLUID 2,5 mg/g GEL OFTALMICOLaboratorios Thea S.A.
- IcelandOftagelSanten Oy*
- FranceSICCAFLUID 2,5 mg/g, gel ophtalmiqueTHEA
- PolandOftagelSanten Oy
- United KingdomAaCarb Carbomer 0.2% eye gelTriOn Pharma Ltd
- GermanyCarbomer EdoDr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh
- NetherlandsCarbomeer Medcor één dosis ooggel 2 mg/gMedcor Pharmaceuticals B.V.
- FinlandLiposicDr. Gerhard Mann, Chem.-pharm. Fabrik GmbH
Authorised across Europe · EMA
The same active substance is authorised in 18 EEA countries. Names it is sold under:
- Austria · Carbomer Agepha
- Belgium · Liposic
- Germany · Carbomer Edo, Liposic
- Denmark · Viscotears
- Spain · Lipolasic
- Finland · Viscotears
- France · Aquarest, Lacrinorm
- United Kingdom (Northern Ireland) · Viscotears, Viscotears Single Dose Unit
- Greece · Liposic, Viscoter
- Iceland · Vidisic
- Italy · Lipovisc
- Luxembourg · Vidisic Edo, Vidisic®
- Netherlands · Liposic, Vidisic Carbogel
- Norway · Viscotears
- Poland · Vidisic
- Portugal · Liposic
- Sweden · Viscotears
- Slovakia · Vidisic
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/9910b2d5-d570-46b5-b1fa-00647993b085 GET /v1/drugs/9910b2d5-d570-46b5-b1fa-00647993b085?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Eye gel",
"routes": [
"Ocular use"
],
"source": "hpra",
"atc_all": [
"S01XA",
"S01XA20"
],
"strength": null,
"pa_number": "PA1107/002/001",
"substances": [
"Carbomer"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Marketed",
"authorised_at": "22/08/2003",
"dispensing_status": "Product not subject to medical prescription",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about künstliche tränenflüssigkeit und sonstige indifferente präparate.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.